Search clinical trials for: HZN-825

Total 2174 results

Horizon Therapeutics Ireland DAC

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Horizon Pharma Ireland, Ltd., Dublin Ireland

Enrolling by invitation

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Korea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
Amgen

Active, not recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Australia, Japan, Canada, Taiwan, Netherlands, Italy, Chile, Greece, Mexico, Germany, France, Argentina, Poland, Turkey, South Africa, United Kingdom
Amgen

Completed

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Alopecia Areata

United States, Canada
Amgen

Terminated

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study (RECAST SLE OLE)

Systemic Lupus Erythematosus

United States, Spain, Serbia, Mexico, Poland, Greece, Argentina, India, Taiwan
Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Sjogren's Syndrome
Horizon Therapeutics Ireland DAC

Recruiting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Idiopathic Inflammatory Myositis

Mexico, United States, Spain, Australia, Italy, United Kingdom, Czechia, Brazil, Germany
Mackay Memorial Hospital
OBI Pharma, Inc

Unknown

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

Ovarian Cancer

Taiwan
Amgen

Completed

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)

Lupus Erythematosus, Systemic

United States, Spain, Serbia, Mexico, Poland, Greece, Argentina, India, Russian Federation, Taiwan, Ukraine
Horizon Therapeutics Ireland DAC

Recruiting

Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus (RECAST DLE)

Discoid Lupus Erythematosus

United States, Germany, Canada, France, Greece, Denmark, Brazil, Bulgaria, Czechia, Argentina, Poland
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
University of California, Davis

Terminated

Effect of Short-term Theta Frequency Stimulation of the Vagus Nerve on Cognition in Patients With Refractory Epilepsy

Refractory Epilepsy
Actegy Ltd.

Terminated

A Short-term Comparative Study of Aerosure for Airway Clearance in Patients With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Actegy Ltd.

Completed

Aerosure and Six Minute Walk Distance in Severe COPD (ACCORD)

COPD

United Kingdom
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
Statens Serum Institut

Completed

Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

Tuberculosis

Netherlands
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Dokuz Eylul University

Recruiting

Whole Body Vibration Training Applied With Different Frequencies in Hypertensive Patients

Hypertension

Turkey
Horizon Therapeutics USA, Inc.

Terminated

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis

United States
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Drexel University

Unknown

Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas

Glioblastoma Multiforme | Astrocytoma Anaplastic Foci
Maastricht University Medical Center

Completed

The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function and Immune Modulation (CRIB)

Healthy Volunteers

Netherlands
Stanley Dudrick's Memorial Hospital

Completed

The Value of Aritficial Diet and Complex Care in Home Nutrition

Dietary Modification

Poland
Wageningen University

Suspended

The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO)

Ulcerative Colitis

Netherlands
Shanghai Mental Health Center

Completed

50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia

Schizophrenia

China
Boundless Bio

Recruiting

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications (STARMAP)

Solid Tumor

United States
Izun Pharma Ltd

Completed

Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer

Oral Mucositis

United States, Israel
Hibernaid, Inc

Unknown

Phase 1 Study of HBN-1

Cardiac Arrest

United States
Hepanova Inc.

Unknown

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

Non-Alcoholic Steatohepatitis (NASH)

United States
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, United States, Bulgaria, Estonia, United Kingdom
GlaxoSmithKline

Completed

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Gastroparesis

United States, Australia, Belgium, United Kingdom, Canada, Sweden
Mayo Clinic
Miami Heart Research Institute Inc.

Not yet recruiting

HTN App for HTN Control and Cardiovascular Health Among African-Americans

Hypertension

United States
University of Pennsylvania

Completed

BP PAL - Hypertension Chat Bot Pilot

Hypertension

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

Atrial Fibrillation

Korea, Republic of
University of Pennsylvania

Completed

Twitter and CV Health

Hypertension | Cardiovascular Disease

United States
University of Pennsylvania

Active, not recruiting

Gamification and Medication Adherence (GAME Adherence)

Hypertension and Hyperlipidemia

United States
Hoffmann-La Roche

Completed

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

United States
Infectious Diseases Research Collaboration, Uganda
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Integration of Hypertension Management in HIV Care in Uganda (PULESAUganda)

Hypertension | HIV/AIDS

Uganda
Infectious Diseases Research Collaboration, Uganda
London School of Hygiene and Tropical Medicine; Makerere University; Ministry... and other collaborators

Active, not recruiting

Leveraging the HIV Platform for Hypertension Control in Uganda (INTEGRATED HIV/HTN) STUDY

Hypertension | HIV

Uganda
University of Illinois at Chicago
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities (AHEAD2)

Hypertension
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Mayo Clinic

Completed

Pilot Study Testing Feasibility of Health Screening at Farm Site

Diabetes Screening | Hyperlipidemia Screening | Hypertension Screening

United States
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
MedtronicNeuro

Completed

Spinal Cord Stimulation Frequency Study

Failed Back Surgery Syndrome

United Kingdom

3

Subscribe